Drug
Hmpl 306
Hmpl 306: highest development phase Phase 3, developed by Hutchmed, United Therapeutics. 4 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Hutchmed, United Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| HMPL-306 tablet NCT07912398 | Phase 3 | Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation |
| HMPL-306 NCT07025018 | Phase 1 | Gliomas Harboring IDH1 and/or IDH2 Mutations |
| HMPL-306 NCT04762602 | Phase 1 | Isocitrate Dehydrogenase Gene Mutation |
| HMPL-306 NCT04272957 | Phase 1 | Acute Myeloid Leukemia |
Latest
No recent events.
Follow Hmpl 306 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.